Does Rallies show 13F holders for IMVT?

Yes. Rallies tracks hedge fund and 13F ownership data for IMVT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IMVT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMVT. It does not provide personalized investment advice.

IMVT (Immunovant, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of May 20, 2026, IMVT trades at $35.27 with a market cap of $5.40B and a P/E ratio of -9.53. IMVT moved +31.65% today. Year to date, IMVT is +1.47%; over the trailing twelve months it is +78.84%. Its 52-week range spans $12.72 to $32.10. Analyst consensus is strong buy with an average price target of $44.88. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IMVT stock?

Hedge funds tracked by Rallies that own IMVT include Farallon Capital, Viking Global, Redmile Group, Soros Fund, and DME Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunovant, Inc. Common Stock.

IMVT Key Metrics

Key financial metrics for IMVT
Metric	Value
Price	$35.27
Market Cap	$5.40B
P/E Ratio	-9.53
EPS	$-2.73
Dividend Yield	0.00%
52-Week High	$32.10
52-Week Low	$12.72
Volume	9.31M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-413.84M
Gross Margin	0.00%

Top Hedge Funds Holding IMVT

Farallon Capital holds 1.55M shares of IMVT, changed +12783.33% as of Mar 31, 2026.
Viking Global holds 1.11M shares of IMVT, changed -20.78% as of Mar 31, 2025.
Redmile Group holds 490.39K shares of IMVT, changed -14.24% as of Mar 31, 2025.
Soros Fund holds 140.00K shares of IMVT, changed +0.00% as of Dec 31, 2023.
DME Capital holds 93.52K shares of IMVT, changed +0.00% as of Mar 31, 2026.

Latest IMVT News

IMVT-1402 Shows 72.7% ACR20 Response in D2T RA; $902M Cash Runway — May 20, 2026
Immunovant climbs as attention shifts back to IMVT-1402 after batoclimab TED setback — May 6, 2026
Immunovant slips as investors keep discounting batoclimab after Phase 3 TED miss — Apr 28, 2026
Immunovant slides as investors weigh April insider sale and mid-April Hold call — Apr 23, 2026
Immunovant climbs as Wall Street lifts targets and shares hover near new highs — Apr 22, 2026

Recent IMVT Insider Trades

Susman Robert Graham sold 2.50K (~$67.98K) on May 1, 2026.
Girao Tiago sold 25.76K (~$763.01K) on Apr 23, 2026.
Stout Jay S sold 2.75K (~$81.57K) on Apr 23, 2026.

IMVT Analyst Consensus

8 analysts cover IMVT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.88.

Common questions about IMVT

Who owns IMVT stock?: Hedge funds tracked by Rallies that own IMVT include Farallon Capital, Viking Global, Redmile Group, Soros Fund, and DME Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunovant, Inc. Common Stock.
Does Rallies show 13F holders for IMVT?: Yes. Rallies tracks hedge fund and 13F ownership data for IMVT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IMVT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMVT. It does not provide personalized investment advice.